CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 912 enrolled
Drug / intervention
exenatide once weekly +1 moredrug
Likely dose
exenatide once weekly 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01029886
NCT01029886Phase 3Completed
CompareCT.gov

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications

AstraZeneca·interventional·Posted Dec 10, 2009·Updated Apr 9, 2015

In Brief

A Phase 3 clinical trial evaluating exenatide once weekly and liraglutide for Type 2 Diabetes Mellitus. Completed, enrolled 912 participants across 108 sites in 21 countries.

Detailed Summary

No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Taiwan
CollaboratorsEli Lilly and Company

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2009
Enrollment StartJan 1, 2010
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.6 years ago

Interventions

exenatide once weeklydrug

subcutaneous injection, 2mg, once weekly

liraglutidedrug

subcutaneous injection, forced titration to 1.8mg, once daily